Mode
Text Size
Log in / Sign up
Phase 3 N=399 Randomized Quadruple-blind Treatment

Epanova® for Lowering Very High Triglycerides

Severe Hypertriglyceridemia

Enrolled (actual)
399
Serious AEs
1.8%
Results posted
Sep 2013
Primary outcome: Primary: Fasting Serum Triglycerides — -4.26; -25.94; -25.46; -30.86 Percent change from baseline — p=0.005

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
placebo (Drug); omefas (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
AstraZeneca
Primary completion
Mar 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Fasting Serum Triglycerides
-4.26; -25.94; -25.46; -30.86 0.005 sig

Summary

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

Eligibility Criteria

Inclusion Criteria

  • Men or women, >=18 years of age.
  • Very high serum TG values in the range >=500 mg/dL and =5.65 mmol/L and 4 weeks prior to Visit 1.
  • Use of oral or injected corticosteroids or anabolic steroids.
  • History of pancreatitis.
  • History of symptomatic gallstone disease, unless treated with cholecystectomy.
  • Uncontrolled diabetes.
  • Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH).
  • History of cancer (other than basal cell carcinoma) in the past 2 years.
  • Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient ischemic attack, unstable congestive heart failure requiring a change in treatment) or revascularization procedure within six months prior to Visit 1.
  • Use of anticoagulants (e.g. warfarin [Coumadin®], coumarin, heparin, enoxaparin, clopidogrel).
  • Presence of an aortic aneurysm or resection of an aortic aneurysm within six months prior to Visit 1.
  • Recent history (within six months prior to Visit 1) or current significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.
  • Poorly controlled hypertension.
  • Any of the following laboratory criteria: serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), glucose, glomerular filtration rate (GFR), platelet count,or hemoglobin outside of study range.
  • Recent history (past 12 months) of drug abuse or alcohol abuse.
  • Exposure to any investigational product, within 4 weeks prior to Visit 1.
  • Presence of any other condition the Investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01242527). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search